Analysts: Actavis-Allergan deal could create a marketing superpower

Valeant's ($VRX) been pursing Allergan ($AGN) for months now, but the California-based drugmaker may soon have another bid, too. Actavis ($ACT) is reportedly preparing to take its second stab at an Allergan deal, which could give Allergan some options. While the two potential transactions look comparable to Leerink Partners analysts Jason Gerberry and Seamus Fernandez from an accretion standpoint, the pair sees "less risk to Allergan brands suffering through the consolidation process" if Allergan combines with Actavis. Such a move "would unite two of the best marketing organizations in pharma," they wrote in a Wednesday note to shareholders. More

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.

AbbVie continues its long-running aggressive TV ad push for Humira last month, while Gilead Sciences takes two spots in the top 10 tally from iSpot.